At present, routine clinical decision making surrounding the selection of treatment interventions are based on BRCA status, anatomical location, hormone receptor status and tumor stage, with very limited attention given to other mediators of DDR—namely homologous recombination—known to confer a BRCAness phenotype similar to BRCA 1 or 2 loss. This evidence concerns the gene NR4A1 and neoplasm.